Lupin Liquidating Japan JV With Yoshindo, Partners With I’Rom For Denosumab Biosimilar
Also Receives UK Approval For Lutio Generic Version Of Spiriva
Executive Summary
Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.
You may also be interested in...
Samsung Bioepis Showcases Denosumab Data
Samsung Bioepis has reported positive Phase I and Phase III trial results for its SB16 proposed denosumab biosimilar to Prolia.
Amneal And mAbxience Ally On Denosumab In US
Amneal has struck a deal with mAbxience to gain US rights to two denosumab biosimilars referencing the Prolia and Xgeva brands that have annual US sales in excess of $4bn.
MGC And GlycoNex Kick Off Denosumab Trial In Japan
Mitsubishi Gas Chemical Company and GlycoNex have begun a Phase I trial in Japan for their SPD8 denosumab biosimilar. The partners are also “actively pursuing global development plans” for the rival to Prolia and Xgeva.